Skip to content
Targeted Therapies in Multiple Myeloma Treatment Decisions

Targeted Therapies in Multiple Myeloma Treatment Decisions

Get the podcast

Vincent Rajkumar Vincent Rajkumar, Divison of Hematology, Mayo Clinic At a section of the hematology meeting talking about newly diagnosed multiple myeloma and the evolving treatments, Vincent Rajkuma

The Audio Journal of Oncology

Vincent Rajkumar

Vincent Rajkumar, Divison of Hematology, Mayo ClinicAt a section of the hematology meeting talking about newly diagnosed multiple myeloma and the evolving treatments,Vincent Rajkumardiscussed new agents such as lenolidamide and thalidomide. The Audio Journal of Oncology asked him how he makes decisions about how to treat multiple myeloma.

Click here for all the interviews from ASH 2005

Tags

ashmyeloma

Next in ASH 2005

All 5 interviews

Interview 5 of 5

Pro-Apoptosis, mTOR Pathways: New Targets for Lymphoma

Pro-Apoptosis, mTOR Pathways: New Targets for Lymphoma

Owen O’Connor Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAH

21 December 2005

Related Episodes

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

Audio Journal of Oncology SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclu

24 Jan 2020
3 min
Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?

Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?

SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irrev

7 Oct 2019
10 min
Audio Journal of Oncology in Advance – March 15th, 2008

Audio Journal of Oncology in Advance – March 15th, 2008

Volume 16 Number 6 (March 15th, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) American Society of Hematology Annual Meeting (December 8-11, 2007

16 Mar 2008